Speakers

Franz Humer, an Austrian by birth, born 1946 and holder of Austrian and Swiss passports. He was educated at the University of Innsbruck where he gained a PhD in Law. He then went on to obtain an MBA at INSEAD in Fontainebleau.

Dr. Humer joined Hoffmann-La Roche in 1995 as Head of the Pharmaceuticals Division and Member of the Board. He was appointed Chief Operating Officer in 1996, Chief Executive Officer in 1998 and in April 2001 he was appointed Chairman of the Board of Directors and Chief Executive Officer. From March 2008 to March 2014 he has been Chairman of the Board of Directors of Roche Holding Ltd.

In July 2006, he became an Honorary Doctor of the University of Basel. He also holds an honorary doctorate from the School of Pharmacy, University of London. In 2013 he was awarded the Singapore Public Service Star (Distinguished Friends of Singapore) Singaporean decoration.

Franz Humer joined the Board of Diageo, the world’s leading spirits company, in 2005 and became its Chairman in 2008. He is also Chairman of the Board of Directors of the International Centre for Missing and Exploited Children and the Humer Foundation.

He is an Independent Director with Citigroup Inc., Chugai Pharmaceuticals Ltd, Bial Pharmaceuticals, Kite Pharma, WISeKey and a member of the Temasek European Advisory Panel.

Axel Baur is a Senior Partner at McKinsey & Company and leader of McKinsey’s Healthcare Systems & Services practice in Asia.

Axel advises top management of the healthcare industry, focusing on public and private health insurance as well as hospital operations. He has also worked with pharmaceutical and medical product companies along their entire value chain.

Recently, Axel has supported pharmaceutical and medical product companies in setting up global operating models; he helped private health insurance companies develop strategies to exploit the growing opportunities in Asia; and he guided large transformations to extract synergies either from acquisitions or reduce significant amounts of the client’s operating costs.

Axel is an expert in innovative care delivery models and is heavily involved in developing McKinsey’s thinking on how healthcare systems can tackle future challenges.

Prior to joining McKinsey, Axel was an entrepreneur building a research-based biotech company.

Axel holds a PhD in molecular biology from Technische Universität Damstadt in Germany, a MBA from INSEAD, and a Diploma in biology from Technische Universität Damstadt.

Adam Gazzaley, M.D., Ph.D. is Professor in Neurology, Physiology and Psychiatry at the UC San Francisco, and the Founding Director of the Neuroscience Imaging Center, Neuroscape Lab and the Gazzaley Lab. The lab explores mechanisms of neuroplasticity and designs, develops and validates new technologies to optimise cognitive abilities via engagement with closed-loop systems using custom-designed video games, brain-computer interfaces and transcranial electrical stimulation.

A major accomplishment of his research has been to expand our understanding of alterations in the aging brain that lead to cognitive decline. His most recent studies explore neuroplasticity and how we can optimise our cognitive abilities via engagement with custom-designed video games, and how this can be bolstered by closed loop systems using brain-computer interfaces and TES

Dr. Gazzaley is co-founder and Chief Science Advisor of Akili Interactive, a company developing therapeutic video games and co-founder and Chief Scientist of JAZZ Venture Partners, a venture capital firm investing in experiential technology to improve human performance. Additionally, he is a scientific advisor for over a dozen technology companies including Apple, GE, Magic Leap and Nielsen.

He has filed multiple patents, authored over 100 scientific articles, and delivered almost 500 invited presentations around the world. He wrote and hosted the nationally-televised PBS special “The Distracted Mind with Dr. Adam Gazzaley”, and co-authored with Dr. Larry Rosen the soon to be released MIT Press book: “The Distracted Mind: Ancient Brains in a High-Tech World”.

Dr. Du is a leading figure and seasoned entrepreneur of China’s biotech industry. She is the founder, Chairman and CEO of ZAI Lab, a premier innovative biopharmaceutical company in China. Dr. Du is recognized for her wide influence on healthcare policies and for her work with various government bodies in China. She served on numerous important government committees including the Planning Committee of the 12th Five Year State Key Healthcare Initiatives.

She was a founding chair of Shanghai Innovation Committee and a founding member and Chairwoman of PhIRDA (China Pharmaceutical Innovation and Research Development Association) Innovation Drug Investment Committee.

Dr. Du has received numerous awards and recognitions. She was voted 2015 Fierce Biotech top 15 women in biopharma. She was also a recipient of Shanghai’s 2010 Magnolia award (an honourable citizenship award) and recipient of Shanghai’s thousand talent program. She was recognized as 2015 R&D Leader of the Year by Bayhelix and China Entrepreneur of the Year in 2008. She was featured by many magazines and newspapers around the world, including WSJ and Forbes for her significant contribution to China’s life science industry and was on the cover of Forbes Asia in 2007.

Professor Darzi is Director of the Institute of Global Health Innovation at Imperial College London. He also holds the Paul Hamlyn Chair of Surgery at Imperial College London, and the Institute of Cancer Research. He is a Consultant Surgeon at Imperial College Hospital NHS Trust and the Royal Marsden NHS Trust.

Professor Darzi leads a large multidisciplinary team across a diverse and impactful portfolio of academic and policy research. His work drives the identification, development and adoption of innovation across international healthcare systems and champions high quality care. He has published over 950 peer-reviewed research papers to date and has developed his status as a leading voice in the field of global health policy and innovation.

He was knighted for his services in medicine and surgery in 2002. In 2007, he was introduced to the United Kingdom’s House of Lords as Professor the Lord Darzi of Denham and appointed Parliamentary Under-Secretary of State at the Department of Health to lead a major review of the NHS, which culminated in the publication of his report, ‘High Quality Care for All: NHS Next Stage Review’, in 2008. Upon relinquishing this Ministerial role in 2009, Professor Darzi was appointed by the Prime Minister as the United Kingdom’s Global Ambassador for Health and Life Sciences until March 2013.

Dr Fidah Alsagoff is a Senior Managing Director at Temasek International Pte Ltd, where he has been since 2008. He is currently Head, Life Sciences. In addition, he is also Executive Director of Sheares Healthcare Management Pte Ltd.

He was previously a Partner at Innosight Ventures Private Limited, and prior to that, was Chief Executive Officer of MOH Holdings. His career also includes nearly a decade in social entrepreneurship where he started up several programs and enterprises catering to hitherto unmet healthcare needs of patients, with the latest enterprise being the establishment of the Singapore Cord Blood Bank.

Dr. Alsagoff graduated from the National University of Singapore with a Bachelors of Medicine and Surgery, and later with a Masters of Medicine in Public Health. He attended INSEAD on a Lee Kuan Yew Scholarship for post-graduate studies, and subsequently graduated with an Executive MBA (with distinction). As valedictorian of his EMBA class, he was awarded the Claude Janssen Prize.

Dr. Alsagoff currently serves on the Board of Trustees of the Singapore University of Technology and Design.

Andrew Conrad, PhD, is the Chief Executive Officer of Verily where he oversees more than 400 engineers, scientists, designers, and medical experts working on a wide spectrum of healthcare-related projects.

Previously, he was Chief Scientific Officer of Laboratory Corporation of America (LabCorp). Dr. Conrad co-founded the National Genetics Institute, where he served as Chief Scientific Officer. Dr. Conrad also founded the California Health and Longevity Institute (CHLI). In addition, he serves as the Chief Scientific Advisor of the North Carolina Research Campus (NCRC), an academic collaboration between Duke University, University of North Carolina, and North Carolina State University.

Dr. Conrad currently serves as a Google Ventures Advisor. He is part of the Health Evolution Summit Leadership Committee and serves as a Summit Chair and is a Working Group Member on the Precision Medicine Initiative.

Dr. Oesterle is a venture partner at New Enterprise Associates (NEA) and serves as a consultant to the Temasek Holdings healthcare group. Steve was formerly Senior Vice President for Medicine and Technology at Medtronic, the world’s largest medical device company, and was a member of its Executive Operating Committee for 14 years. By forging relationships with global technology partners and technical universities, he oversaw long term internal technology investments while participating in strategic corporate investments in emerging private companies.

He also served as a member of Medtronic’s Business Development and Strategy Committee that approved all corporate acquisitions. During his tenure at Medtronic, Steve served on more than 20 boards as a director or observer and built a strong and enduring profile for Medtronic in the global venture capital and private equity communities.

Steve graduated summa cum laude from Harvard and received his medical degree with honours from Yale; he completed his internship and residency at Massachusetts General Hospital. Following medical school, he completed a fellowship in Interventional Cardiology at Stanford and then served on the faculty at Stanford and Harvard Medical Schools and directed the Invasive Cardiology Services at Massachusetts General Hospital and Stanford.

Central Region Regional Chief Medical Director (1/2015 to present)

Medical Director of the Surgical Services Clinical Program for Intermountain Healthcare (2010 – 2015)

Chairman of the Department of Surgery at Intermountain Medical Center (2007 – 2014)

Adjunct Associate Professor of Surgery at the University of Utah School of Medicine

Dr. Ott received his medical degree from the University Of Utah School Of Medicine. He trained in general surgery at Johns Hopkins Hospital. Subsequently he completed a Society of Surgical Oncology fellowship also at Johns Hopkins Hospital. He practiced surgical oncology at Massachusetts General Hospital and was a faculty member of the Harvard School of Medicine (1997 – 2002) prior to being recruited to Intermountain Healthcare.

He has received multiple teaching awards for his efforts in educating medical students and residents. He has also received multiple community awards for his contribution to excellence in patient outcomes and healthcare delivery.

In addition to his administrative, leadership, and educational responsibilities; he is also a practicing surgical oncologist specializing in Hepatobiliary and Pancreatic tumors, Sarcoma, as well complex upper gastrointestinal surgery, and other rare tumors.

His leadership interests center on recruiting physician/surgeons to participate in clinical program building and outcomes analysis and research. He has led corporate wide initiatives across the 22 hospitals in the Intermountain Healthcare system to reduce the cost of surgical procedures by 100 millions of dollars from 2012 – 2015. In addition to overseeing and improving healthcare delivery in the Intermountain Healthcare’s five Central Region hospitals, he is also currently responsible to help make Intermountain Medical Center one of the top 5 hospitals in America.

He has served as the physician champion for Intermountain Medical Center’s participation in the National Surgical Quality Improvement Program. He also has a strong interest in workplace wellness and served as a Board Member for the Wellness Councils of America (WELCOA) for 10 years.

Michael is a General Partner at Flare Capital Partners. Prior to co-founding Flare Capital Partners, Michael was the founding General Partner of Flybridge Capital Partners where he led the firm’s healthcare investments. Current and prior board seats include BlueTarp Financial, EndoGastric Solutions, Explorys, Functional Neuromodulation, HealthVerity, Iora Health, MicroCHIPS, Nuvesse, PolyRemedy, Predictive Biosciences, Predilytics, T2 Biosystems, TARIS Biomedical, VidSys and Welltok.

Previously, Michael focused on emerging-growth company financings with Polaris Venture Partners, was a senior vice president and founding partner of GCC Investments, and help positions at Wasserstein Perella & Co., Morgan Stanley & Co. and Credit Suisse First Boston.

Michael currently serves as chairman of the Entrepreneurship Committee of the Massachusetts Information Collaborative and on the Investment Committee for the Partners Innovation Fund and Massachusetts Eye & Ear Infirmary. Michael also serves on the Industry Advisory Board of the Cleveland Clinic, as well as serving on several other boards including the New England Investors’ Committee of Capital Innovation. He was the former chairman of the New England Venture Capital Association and on the Executive Committee of the board of the National Venture Capital Association. Named by the Boston Globe as the “Go-To” investor for life sciences, healthcare and medical devices and a Mass High Tech All-Star, Michael earned a B.A. with honors in chemistry from Williams College and an M.B.A. from Harvard Business School.

Michael authors a blog focused on venture capital, innovation and healthcare at www.ontheflyingbridge.com